合理设计的耐酶基组件用于瘤治疗中的等离子膜向
Shijin Zhang1, Xuewen Gong1, Qinchuan Wei1
1National Engineering Research Centre of Ophthalmology and Optometry, School of Biomedical Engineering, Eye Hospital, Wenzhou Medical University, Wenzhou, 325027, China.
Advanced healthcare materials
|July 3, 2023
概括
研究人员开发了一种新型 (tF4),可以自组装成纳米结构,以向血膜 (PM) 用于癌症治疗. 这种耐酶通过调节细胞功能和增加死亡受体表达来诱导癌细胞死亡.
科学领域:
- 生物技术是生物技术.
- 纳米医学是一种纳米医学.
- 癌症研究 癌症研究
背景情况:
- 类对向癌症治疗至关重要,旨在增强特异性并克服多种药物耐药性.
- 用自组装来向血膜 (PM) 仍然是癌症治疗策略中尚未探索的领域.
研究的目的:
- 开发一种新型的,耐酶的,自我组装的,用于向癌细胞等离子体膜 (PM).
- 研究组合与PM相互作用并诱导癌细胞死亡的机制.
主要方法:
- 一个新型性分子 (tF4) 的合成和表征.
- 研究tF4自组装成囊泡纳米结构的研究.
- 分析tF4组件与等离子膜 (PM) 通过键和疏水相互作用的相互作用.
- 评估tF4诱导的细胞变化,包括细胞骨重塑和死亡受体表达.
主要成果:
- 合成tF4表现出对基酶的耐药性.
- tF4自组装成与癌细胞PM相互作用的纳米结构.
- tF4组件诱导了应力纤维的形成,细胞骨的重建,并增加了死亡受体的表达 (DR4/5).
- DR4/5的升级触发了外在的caspase-8信号通路,导致癌细胞死亡.
结论:
- 已经建立了一个新的策略,使用耐酶,向PM的自组合来治疗癌症.
- tF4代表了开发基于的新型癌症治疗的有希望的候选人.
- 这些发现突出了通过PM向纳米结构调节细胞功能和死亡受体通路的潜力.
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
Cancer Cell Migration through Invadopodia
2.3K
Invadosome is a broad category of cell surface structures with proteolytic activity that degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
2.3K
Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K


